If you have been comparing research peptides, you have probably hit this exact moment of confusion: one site says retatrutide, another says Retaklik, and you are left wondering whether you are looking at two different things or the same thing wearing a different hat. It is a fair question, and the internet does a stellar job of muddying it. So let us settle it plainly: is Retaklik the same as retatrutide?
Key takeaways
- Retatrutide is the name of the compound — Eli Lilly’s investigational triple-agonist, LY3437943.
- Retaklik is a brand/format name for retatrutide supplied as a research pen, rather than a separate molecule.
- They are related, not identical terms: one is the science, one is the product packaging.
- Research-supplied peptides are not the same formulation used in clinical trials — which is exactly why a COA matters.
The short answer
Retaklik is not a different compound from retatrutide — it is a branded research-pen format that delivers retatrutide. Think of it the way you would a high-street coffee: “flat white” is the drink, the café’s name is the brand serving it. Retatrutide is the drink; Retaklik is one of the names on the cup. The peptide inside is retatrutide; “Retaklik” tells you the format and source, not a new molecule.
What is retatrutide?
Retatrutide is a single peptide that activates three receptors at once — GLP-1, GIP and glucagon — which is why researchers describe it as a “triple agonist”. It is being developed by Eli Lilly and is still in clinical trials; its Phase 2 data was published in the New England Journal of Medicine, and Lilly has summarised the programme in its own investor release. For the full molecular detail, see our retatrutide research compound profile.
So what is Retaklik?
Retaklik is a brand name used for retatrutide presented in a pre-set research pen, as opposed to a traditional vial-and-syringe setup. The appeal of the pen format is convenience for measured research handling — the “klik” in the name is a nod to the click-dose mechanism. The compound it delivers is retatrutide. We cover the pen specifically in our Retaklik UK guide, including how the dial works.
Vial vs pen: which should you choose?
| Retatrutide vial | Retaklik pen | |
|---|---|---|
| Compound | Retatrutide | Retatrutide |
| Format | Freeze-dried powder, reconstituted by you | Pre-set research pen with click mechanism |
| Setup | Requires reconstitution (see our guide) | More convenient, less prep |
| Best for | Flexibility and value per mg | Convenience and consistency |
Neither is “better” in the abstract — it is a trade-off between flexibility and convenience. If you like controlling concentration yourself, the vial wins. If you would rather skip the mixing, the pen does.
The important caveat nobody should skip
Here is the bit the hype merchants gloss over. Research-supplied retatrutide — whether labelled Retaklik or sold as a plain vial — is not the identical, regulator-checked formulation used in Eli Lilly’s clinical trials. It is supplied for laboratory research only, and quality genuinely varies between suppliers. Retatrutide has no MHRA authorisation and cannot legally be sold as a medicine in the UK. That is not a technicality; it is the whole reason a batch-specific Certificate of Analysis matters. The brand on the box tells you the format. The COA tells you the truth.
What to check before you buy either
- A batch-specific third-party COA (Janoshik or similar) confirming identity and ≥99% purity.
- Honest research-use-only labelling — no miracle claims.
- A real UK supplier with dispatch and support.
- Sensible pricing — see our retatrutide UK price guide.
You can see current UK stock of both formats on our retatrutide UK page, including retatrutide 2.0 (45mg).
Frequently asked questions
Is Retaklik the same as retatrutide?
Effectively yes in terms of the compound — Retaklik is a branded research-pen format that delivers retatrutide. It is not a different molecule; it is a different presentation.
Is Retaklik a vial or a pen?
Retaklik refers to the pen format. Plain retatrutide is usually supplied as a freeze-dried vial you reconstitute yourself.
Is Retaklik the same as the retatrutide used in trials?
No. Research-supplied peptides — under any brand — are not the regulator-verified clinical-trial formulation. Always rely on a batch COA for what is actually in the product.
Which is better, the pen or the vial?
The pen is more convenient; the vial offers more control over concentration and often better value per mg. It comes down to preference.
Is Retaklik legal in the UK?
Retatrutide is not a controlled drug, but it has no UK medicine authorisation, so Retaklik and retatrutide can only be sold for research use — not for human consumption.
The bottom line
Retaklik and retatrutide are not two rival compounds — one is the molecule, the other is a branded pen format that delivers it. Choose vial or pen on convenience versus control, but choose your supplier on the COA. Browse both on our retatrutide UK page.
This article is for informational and research purposes only. Retatrutide is an investigational compound supplied for laboratory research use only and is not for human consumption. Nothing here is medical advice.